Cargando…

Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole

Itraconazole (ICZ) is a broad spectrum antifungal drug, but used as second or third line therapy due to its low and erratic oral bioavailability. This work was carried out to prepare and characterize matrix type lipid-polymer hybrid nanoparticles (LPHNPs) for dissolution enhancement of ICZ. LPHNPs w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yousaf, Rimsha, Khan, Muhammad Imran, Akhtar, Muhammad Furqan, Madni, Asadullah, Sohail, Muhammad Farhan, Saleem, Ammara, Irshad, Kanwal, Sharif, Ali, Rana, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010992/
https://www.ncbi.nlm.nih.gov/pubmed/36925532
http://dx.doi.org/10.1016/j.heliyon.2023.e14281
_version_ 1784906289784029184
author Yousaf, Rimsha
Khan, Muhammad Imran
Akhtar, Muhammad Furqan
Madni, Asadullah
Sohail, Muhammad Farhan
Saleem, Ammara
Irshad, Kanwal
Sharif, Ali
Rana, Maria
author_facet Yousaf, Rimsha
Khan, Muhammad Imran
Akhtar, Muhammad Furqan
Madni, Asadullah
Sohail, Muhammad Farhan
Saleem, Ammara
Irshad, Kanwal
Sharif, Ali
Rana, Maria
author_sort Yousaf, Rimsha
collection PubMed
description Itraconazole (ICZ) is a broad spectrum antifungal drug, but used as second or third line therapy due to its low and erratic oral bioavailability. This work was carried out to prepare and characterize matrix type lipid-polymer hybrid nanoparticles (LPHNPs) for dissolution enhancement of ICZ. LPHNPs were prepared using solvent diffusion/emulsification technique. Matrix LPHNPs were composed of chitosan (polymer), glyceryl monostearate (lipid) and poloxamer 188 (stabilizer). LPHNPs loaded with ICZ (LPHNPs-1, LPHNPs-2, LPHNPs-3 and LPHNPs-4) were developed using varying concentration of chitosan whereas LPHNPs (LPHNPs-5, LPHNPs-6, LPHNPs-7 and LPHNPs-8) were prepared using varying concentrations of poloxamer 188. LPHNPs loaded with ICZ were further evaluated for entrapment efficiency, particle size, polydispersity index (PDI), zeta potential and dissolution profiles at biorelevant pH conditions. The particle size (LPHNPs-1 to LPHNPs-4) was found to be in range of 421–588 nm with PDI values 0.34–0.41. The particles size of LPHNPs-5 to LPHNPs-8 was found to be in range of 489–725 nm with PDI 0.34–0.74. The entrapment efficiency of LPHNPs-1 to LPHNPs-4 was found to be in range of 85.21%–91.34%. The entrapment efficiency of LPHNPs-5 to LPHNPs-8 was found to be in range 78.32%–90.44%. . The scanning electron microscopy of optimized formulations LPHNPs-1 and LPHNPs-5 indicated formation of oval shaped nanoparticles. DSC thermogram of ICZ loaded LPHNPs also depicted the conversion of crystalline form of ICZ into amorphous form demonstrating the internalization and dissolution enhancement of drug in the hybrid matrix. The cumulative drug dissolved at acidic pH 1.2 was found to be 23.3% and 19.8% for LPHNPs-1 and LPHNPs-5 respectively. Similarly at basic pH values 7.4, cumulative amount of drug dissolved was 90.2% and 83.4% for LPHNPs-1 and LPHNPs-5 respectively. Drug dissolution kinetics exhibited fickian diffusion best described by Korse-meyer Peppas model. The results suggested that chitosan and glyceryl monostearate based matrix LPHNPs could be used as promising approach for dissolution enhancement of ICZ which could further increase its bioavailability.
format Online
Article
Text
id pubmed-10010992
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100109922023-03-15 Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole Yousaf, Rimsha Khan, Muhammad Imran Akhtar, Muhammad Furqan Madni, Asadullah Sohail, Muhammad Farhan Saleem, Ammara Irshad, Kanwal Sharif, Ali Rana, Maria Heliyon Research Article Itraconazole (ICZ) is a broad spectrum antifungal drug, but used as second or third line therapy due to its low and erratic oral bioavailability. This work was carried out to prepare and characterize matrix type lipid-polymer hybrid nanoparticles (LPHNPs) for dissolution enhancement of ICZ. LPHNPs were prepared using solvent diffusion/emulsification technique. Matrix LPHNPs were composed of chitosan (polymer), glyceryl monostearate (lipid) and poloxamer 188 (stabilizer). LPHNPs loaded with ICZ (LPHNPs-1, LPHNPs-2, LPHNPs-3 and LPHNPs-4) were developed using varying concentration of chitosan whereas LPHNPs (LPHNPs-5, LPHNPs-6, LPHNPs-7 and LPHNPs-8) were prepared using varying concentrations of poloxamer 188. LPHNPs loaded with ICZ were further evaluated for entrapment efficiency, particle size, polydispersity index (PDI), zeta potential and dissolution profiles at biorelevant pH conditions. The particle size (LPHNPs-1 to LPHNPs-4) was found to be in range of 421–588 nm with PDI values 0.34–0.41. The particles size of LPHNPs-5 to LPHNPs-8 was found to be in range of 489–725 nm with PDI 0.34–0.74. The entrapment efficiency of LPHNPs-1 to LPHNPs-4 was found to be in range of 85.21%–91.34%. The entrapment efficiency of LPHNPs-5 to LPHNPs-8 was found to be in range 78.32%–90.44%. . The scanning electron microscopy of optimized formulations LPHNPs-1 and LPHNPs-5 indicated formation of oval shaped nanoparticles. DSC thermogram of ICZ loaded LPHNPs also depicted the conversion of crystalline form of ICZ into amorphous form demonstrating the internalization and dissolution enhancement of drug in the hybrid matrix. The cumulative drug dissolved at acidic pH 1.2 was found to be 23.3% and 19.8% for LPHNPs-1 and LPHNPs-5 respectively. Similarly at basic pH values 7.4, cumulative amount of drug dissolved was 90.2% and 83.4% for LPHNPs-1 and LPHNPs-5 respectively. Drug dissolution kinetics exhibited fickian diffusion best described by Korse-meyer Peppas model. The results suggested that chitosan and glyceryl monostearate based matrix LPHNPs could be used as promising approach for dissolution enhancement of ICZ which could further increase its bioavailability. Elsevier 2023-03-09 /pmc/articles/PMC10010992/ /pubmed/36925532 http://dx.doi.org/10.1016/j.heliyon.2023.e14281 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Yousaf, Rimsha
Khan, Muhammad Imran
Akhtar, Muhammad Furqan
Madni, Asadullah
Sohail, Muhammad Farhan
Saleem, Ammara
Irshad, Kanwal
Sharif, Ali
Rana, Maria
Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole
title Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole
title_full Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole
title_fullStr Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole
title_full_unstemmed Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole
title_short Development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (LPHNPs) for oral delivery of itraconazole
title_sort development and in-vitro evaluation of chitosan and glyceryl monostearate based matrix lipid polymer hybrid nanoparticles (lphnps) for oral delivery of itraconazole
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010992/
https://www.ncbi.nlm.nih.gov/pubmed/36925532
http://dx.doi.org/10.1016/j.heliyon.2023.e14281
work_keys_str_mv AT yousafrimsha developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole
AT khanmuhammadimran developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole
AT akhtarmuhammadfurqan developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole
AT madniasadullah developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole
AT sohailmuhammadfarhan developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole
AT saleemammara developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole
AT irshadkanwal developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole
AT sharifali developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole
AT ranamaria developmentandinvitroevaluationofchitosanandglycerylmonostearatebasedmatrixlipidpolymerhybridnanoparticleslphnpsfororaldeliveryofitraconazole